APOE3-R136S mutation confers resilience against tau pathology via cGAS-STING-IFN inhibition
暂无分享,去创建一个
M. Wong | Li Fan | Li Gan | Pearly Ye | Chloe Lopez-Lee | Tark Patel | Jingjie Zhu | Kendra Norman | Eileen Ruth Torres | Wenjie Luo | Shiaoching Gong | Subhash C. Sinha | S. Mok | Mingrui Zhao | Sarah A Naguib | Maitreyee Bhagwat | Se-In Lee
[1] J. Fahel,et al. Blockade of mGluR5 in astrocytes derived from human iPSCs modulates astrocytic function and increases phagocytosis , 2023, Frontiers in immunology.
[2] J. Ulrich,et al. APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread , 2023, Cell.
[3] Brian P. Grone,et al. The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation , 2023, Nature Neuroscience.
[4] S. DeKosky,et al. Genome-wide analysis identifies novel loci influencing plasma apolipoprotein E concentration and Alzheimer’s disease risk , 2023, Molecular psychiatry.
[5] Li Li,et al. Astrocytic response mediated by the CLU risk allele inhibits OPC proliferation and myelination in a human iPSC model , 2023, Cell reports.
[6] M. Takatama,et al. Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ 40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease. , 2023, Journal of Alzheimer's disease : JAD.
[7] D. Holtzman,et al. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy , 2023, Nature.
[8] B. Bacskai,et al. Reduced excitatory neuron activity and interneuron-type-specific deficits in a mouse model of Alzheimer’s disease , 2022, Communications Biology.
[9] Y. Asmann,et al. Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination , 2022, Molecular Neurodegeneration.
[10] William T. Ralvenius,et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes , 2022, Nature.
[11] Justin S. Sanchez,et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia , 2022, Acta Neuropathologica.
[12] D. Harvey,et al. High-Density Lipoprotein Changes in Alzheimer’s Disease Are APOE Genotype-Specific , 2022, Biomedicines.
[13] G. Rabinovici,et al. Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials , 2022, The Journal of Nuclear Medicine.
[14] Holden C. Williams,et al. APOE modulates microglial immunometabolism in response to age, amyloid pathology, and inflammatory challenge , 2022, bioRxiv.
[15] Virginia M. Y. Lee,et al. AD-linked R47H-TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation , 2021, Science Translational Medicine.
[16] C. Jack,et al. APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia , 2021, Science Translational Medicine.
[17] Gonçalo Lopes,et al. New Open-Source Tools: Using Bonsai for Behavioral Tracking and Closed-Loop Experiments , 2021, Frontiers in Behavioral Neuroscience.
[18] Hui Zheng,et al. Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology , 2021, Molecular neurodegeneration.
[19] V. Janout,et al. Single Nucleotide Polymorphism rs11136000 of CLU Gene (Clusterin, ApoJ) and the Risk of Late-Onset Alzheimer’s Disease in a Central European Population , 2020, Neurochemical Research.
[20] P. Giussani,et al. The role of Sphingolipids in myelination and myelin stability and their involvement in childhood and adult demyelinating disorders , 2020, Journal of neurochemistry.
[21] Yilan Xu,et al. GABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment , 2020, Frontiers in Neuroscience.
[22] B. McEwen,et al. Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer’s molecular signatures , 2019, Proceedings of the National Academy of Sciences.
[23] P. Scheltens,et al. Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer’s disease , 2019, Molecular Psychiatry.
[24] Seungpyo Hong,et al. Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers , 2019, Experimental & Molecular Medicine.
[25] Matthias Bethge,et al. DeepLabCut: markerless pose estimation of user-defined body parts with deep learning , 2018, Nature Neuroscience.
[26] James E. Goldman,et al. White matter changes in Alzheimer’s disease: a focus on myelin and oligodendrocytes , 2018, Acta Neuropathologica Communications.
[27] A. Fagan,et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy , 2017, Nature.
[28] Markus Glatzel,et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. , 2017, Immunity.
[29] I. Amit,et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease , 2017, Cell.
[30] Shay Ohayon,et al. Open Ephys: an open-source, plugin-based platform for multichannel electrophysiology , 2017, Journal of neural engineering.
[31] Geoffrey M. Barrett,et al. Tau Pathology Induces Excitatory Neuron Loss, Grid Cell Dysfunction, and Spatial Memory Deficits Reminiscent of Early Alzheimer’s Disease , 2017, Neuron.
[32] E. Boyden,et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia , 2016, Nature.
[33] Jennifer Luebke,et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation , 2015, Nature Neuroscience.
[34] Arthur Konnerth,et al. Neuronal hyperactivity – A key defect in Alzheimer's disease? , 2015, BioEssays : news and reviews in molecular, cellular and developmental biology.
[35] C. Glass,et al. Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signaling. , 2014, Cell metabolism.
[36] G. Bloom. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. , 2014, JAMA neurology.
[37] K. Seyb,et al. Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. , 2014, The Journal of clinical investigation.
[38] C. DeCarli,et al. Myelin injury and degraded myelin vesicles in Alzheimer's disease. , 2014, Current Alzheimer research.
[39] Yanhui Liu,et al. Identification of Tmem10 as a Novel Late-stage Oligodendrocytes Marker for Detecting Hypomyelination , 2013, International journal of biological sciences.
[40] Edward O. Mann,et al. Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model , 2012, Cell.
[41] Marcel Martin. Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .
[42] L. Mucke,et al. Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.
[43] B. Hemmings,et al. Carboxy-Terminal Modulator Protein (CTMP) is a mitochondrial protein that sensitizes cells to apoptosis. , 2009, Cellular signalling.
[44] Noo Li Jeon,et al. Presynaptic Regulation of Astroglial Excitatory Neurotransmitter Transporter GLT1 , 2009, Neuron.
[45] M. Pangalos,et al. Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels , 2008, The Journal of Neuroscience.
[46] Y. Uchijima,et al. Carboxy-terminal modulator protein induces Akt phosphorylation and activation, thereby enhancing antiapoptotic, glycogen synthetic, and glucose uptake pathways. , 2007, American journal of physiology. Cell physiology.
[47] R. Mahley,et al. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[48] A. Fagan,et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[49] Hugo Vanderstichele,et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.
[50] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[51] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[52] E. Masliah,et al. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. , 1996, Annals of neurology.